可溶性E-CD在膀胱移行细胞癌患者尿中的含量及其临床意义

目的：检测可溶性上皮性钙粘附素（sE-CD）在膀胱移行细胞癌患者尿中的含量及其临床意义。方法：用ELISA方法测定31例膀胱移行细胞癌患者、17例泌尿系良性病变患者及11例正常人尿中sE—CD的水平．对比各组间指标并结合肿瘤生物学性质进行相关性分析。结果：膀胱移行细胞癌患者尿中sE—CD水平高于正常人和泌尿系良性病变患者：尿中sE-CD水平与膀胱移行细胞癌的分期分级呈正相关．与肿瘤大小及个数无关：复发患者尿中sE—CD水平高于初发患者。结论：膀胱移行细胞癌患者尿中sE—CD水平升高．与膀胱肿瘤的生物学性质有密切关系，对于早期诊断膀胱移行细胞癌以及估计肿瘤的生物学性质具有重要价值

The level of urine soluble E-cadherin in patients with bladder transitional cell cancer and its clinical significance

Objective:To investigate the level and its clinical significance of urine soluble E-cadherin (sE-CD)in patients with bladder transitional cell cancer(TCC). Methods: The sE-CD was measured by enzyme-linked immunosorbent assay (ELISA) in the urine samples of 11 normal control, 31 patients with TCC and 17 patients with benign urologic disease. Results:The level of urine sE-CD in patients with TCC was higher than patients with benign disorder of urinary system and normal control. There were significant correlation between sE-CD level with the tumor grade and stage, but no significant correlation with the magnitude and number of the tumor. Conclusions:The higher expression of sE-CD in urine is very closely linked with the biological behaviors of bladder TCC, and The detection of urinary sE-CD play an important role in the early diagnosis of bladder TCC.